Adult HTN & angina Initially 5 mg once daily, may be increased to a max dose of 10 mg depending on individual patient's response. Childn & adolescent 6-17 yr HTN 2.5 mg once daily as starting dose, up-titrated to 5 mg once daily if BP goal is not achieved after 4 wk.
Hypersensitivity to dihydropyridine derivatives or amlodipine. Severe hypotension. Shock (including cardiogenic shock). Obstruction of outflow tract of left ventricle eg, high grade aortic stenosis. Haemodynamically unstable heart failure after acute MI.
Safety & efficacy of amlodipine in hypertensive crisis has not been established. Caution in patients w/ cardiac failure; may increase risk of future CV events & mortality. Cautious dose selection & start at the lower end of dosing range in patients w/ mild to moderate hepatic impairment. Initiate treatment at the lowest dose & slowly titrate in patients w/ severe hepatic impairment. Use in pregnancy is only recommended when there is no safer alternative. Continue/discontinue breast-feeding or continue/discontinue therapy during lactation. No data are available in childn <6 yr. Increase dose w/ care in elderly.
Increased exposure w/ strong or moderate CYP3A4 inhibitors [eg, PIs, azole antifungals, macrolides (eg, erythromycin or clarithromycin), verapamil or diltiazem]. Possible decreased plasma conc w/ CYP3A4 inducers (eg, rifampicin, Hypericum perforatum). Increased bioavailability w/ grapefruit or grapefruit juice. Additive BP-lowering effects w/ other antihypertensives. Due to risk of hyperkalemia, avoid co-administration of Ca channel blockers eg, amlodipine in patients susceptible to malignant hyperthermia & in the management of malignant hyperthermia (dantrolene infusion).
C08CA01 - amlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Sign Out
